SABCS会议亮点:AI和数字病理学在早期乳腺癌中的应用
AI, Digital Pathology in Early Breast Cancer Among Highlights at SABCS
SABCS会议上将重点讨论AI和数字病理学在早期乳腺癌中的应用,包括如何通过图像工具确定化疗或内分泌治疗的需要。此外,还将介绍新型抗体-药物偶联物和内分泌疗法等研究。
— Virginia Kaklamani also previews studies on antibody-drug conjugates, endocrine therapy, and more
by Gregory Laub, Senior Director, Video, MedPage Today
November 2, 2026 • 3 min read
The use of artificial intelligence (AI) and digital pathology in early breast cancer will be a major theme at the upcoming San Antonio Breast Cancer Symposium (SABCS), with new research exploring whether image-based tools can help determine which patients need chemotherapy or extended endocrine therapy.
In this exclusive MedPage Today video, Virginia Kaklamani, MD, DSc, of the University of Texas at San Antonio Health Science Center, who is co-director of SABCS, previews some of the early breast cancer research to watch at this year's meeting, including studies on novel antibody-drug conjugates and endocrine therapy, genomic studies, and a debate on the use of trastuzumab deruxtecan (T-DXd; Enhertu) in the neoadjuvant versus adjuvant setting for HER2-positive disease.
Following is a transcript of her remarks:
Hello, my name is Virginia Kaklamani from UT Health San Antonio, and I'm one of the co-directors of the San Antonio Breast Cancer Symposium.
So for this year's symposium, our 49th year, we're going to have a lot of really interesting abstracts, especially in the early-stage setting, looking at AI. So looking at digital pathology and how this digital pathology can actually help us determine who needs chemotherapy and who doesn't need chemotherapy, who needs extended endocrine therapy, and so forth. This is really a new era where we have a lot of tools available so that instead of taking a specimen, sending it to a laboratory thousands of miles away, and analyzing it, now with digital pathology, all we need to do is just take a picture and send that picture over and then that picture gets analyzed, and really the information that we get may actually be as good, if not better, than the information we get from doing genomic assays on specific tumor specimens.
So this is going to help, I think, in the future because it'll allow us to do these tests quicker and also cheaper. And we can do them from anywhere in the world, whereas right now these laboratories sometimes in certain countries have specific regulations.
So I think this is kind of the biggest news out of SABCS this year, but there's so many other things. We have new novel antibody-drug conjugates. We're going to be looking at endocrine therapy in the early-stage setting and so forth, and a lot of other genomic presentations that'll really help us treat our patients better.
This year we expect more than 11,000 people to come to San Antonio. We always have many medical oncologists, surgical oncologists, radiation oncologists, advocates. I think the strength of SABCS is the presence of our patient advocates and the inclusion of our patient advocates through the program and the different sessions that we have.
We have several special sessions that are looking at lobular carcinoma, looking at obesity and breast cancer, GLP-1 agonists, really the talk of the past -- what, 5, 10 years -- and how GLP-1s can help improve health in our patients with breast cancer, potentially also improve outcomes in our breast cancer patients.
So a lot of things happening in the symposium, from educational sessions, state-of-the-art sessions, debate. The big debate this year is going to be whether to give T-DXd in the neoadjuvant or adjuvant setting in patients with early-stage HER2-positive disease. So the 5 days that the meeting is going on is really going to be crazy, but it's going to be a lot of fun data to discuss.
来源:MedPage Today · medpagetoday.com